– 19 Abstracts Will Feature the Latest
Advances in the Company’s HIV, COVID-19 and Viral Hepatitis
Research Programs –
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the
upcoming presentation of new data from the company’s HIV, hepatitis
C virus (HCV), and COVID-19 research and development programs at
the 28th Conference on Retroviruses and Opportunistic Infections
(virtual CROI 2021) taking place from March 6-10. The breadth of
data at the meeting reflects Gilead’s longstanding commitment to
applying its scientific innovation toward addressing some of the
world’s most challenging viruses and advancing global health.
“The impact of COVID-19 on its own has been devastating for
public health, and the disruption to the healthcare system and
worsening health inequity driven by the pandemic are threatening to
set back efforts to end the HIV epidemic and the hard-won progress
toward HCV elimination,” said Diana Brainard, MD, Senior Vice
President, Virology Therapeutic Area, Gilead Sciences. “Now more
than ever, there is an urgent need to accelerate and advance
innovative antiviral research to help prevent transmission and
provide a portfolio of therapeutic options for those affected. The
data we will present at CROI 2021 demonstrate the important
scientific advancements we have made to help address the needs of
people living with HIV and HCV, and those affected by
COVID-19.”
HIV Research
At CROI 2021, Gilead will share new findings on daily and
long-acting HIV prevention and treatment strategies, as well as
updates from the company’s continued pursuit of a cure for HIV.
Data will include Phase 2/3 CAPELLA trial results evaluating the
company’s investigational, long-acting HIV-1 capsid inhibitor,
lenacapavir, in heavily treatment-experienced people with multidrug
resistant HIV-1 infection. The company will also present data from
a pre-clinical study evaluating lenacapavir for HIV pre-exposure
prophylaxis (PrEP).
Insights from Gilead’s cure research program include new data on
vesatolimod, an investigational toll-like receptor 7 (TLR7)
agonist, as well as analyses of analytical treatment interruption
studies using mathematical modelling techniques and approaches for
assessing broadly neutralizing antibodies (bNAbs) sensitivity.
HIV treatment research includes long-term data from two Phase 3
studies (Study 1489 and Study 1490) that demonstrated the safety
and efficacy profile of the once-daily, single tablet regimen,
Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir
alafenamide 25 mg tablets, B/F/TAF) compared with dolutegravir
(DTG)-containing regimens for the treatment of HIV-1 infection in
treatment-naïve adults. The data include a sub-analysis in
participants with certain transmitted drug resistance and
cumulative outcomes from an open-label extension (OLE) phase of two
Phase 3 studies evaluating treatment outcomes in participants who
initiated therapy with Biktarvy and those who switched to Biktarvy
from a DTG-containing regimen.
HCV Research
Results from the ACTG A5360 Study will be presented on the
minimal monitoring (MINMON) approach to HCV treatment with Epclusa®
(400 mg sofosbuvir/100 mg velpatasvir) across a range of settings
and in key populations most impacted by the virus.
Please refer to the full Prescribing Information for complete
monitoring information for Epclusa.
COVID-19 Research
Gilead will also present preliminary data from the ongoing Phase
2/3 CARAVAN study evaluating the safety and efficacy of Veklury®
(remdesivir) for the treatment of hospitalized pediatric patients
two months to 17 years of age. Additional data from an open-label,
Phase 3 trial evaluating Veklury's impact on kidney function in
patients with moderate COVID-19 will also be presented. Veklury is
the only approved antiviral for the treatment of COVID-19.
Select accepted abstracts are as follows:
Investigational Long-Acting HIV
Research (Lenacapavir)
Potent Antiviral Activity of Lenacapavir
in Phase 2/3 in Heavily ART-experienced PWH
Long-acting HIV Capsid Inhibitor Effective
as PrEP in a SHIV Rhesus Macaque Model
Clinical Evaluation of Drug Interactions
With Oral Lenacapavir and Probe Drugs
Activity and Resistance Characterization
of the HIV Capsid Inhibitor Lenacapavir
Pharmacokinetics of Lenacapavir, an HIV-1
Capsid Inhibitor, in Hepatic Impairment
HIV Treatment Research
Four-Year Outcomes of B/F/TAF in
Treatment-Naïve Adults
HIV With Transmitted Drug Resistance is
Durably Suppressed by B/F/TAF at Week 144
HIV-1 DNA Genotyping is Often Variable in
Repeat Testing From Single Blood Draws
Drug Interactions With Once-Daily B/F/TAF
in Combination With Once-Weekly Rifapentine
HIV Prevention Research
Ultrasensitive HIV-1 Drug-Resistance
Analysis in the DISCOVER PrEP Trial
HIV Cure Research
Mathematical Modeling of Predictors of
Posttreatment Control in HIV Cure Trials
HIV Rebound in Controllers is Associated
With Specific Fecal Microbiome Profile
Evaluation of bNAb Sensitivity by
Genotyping and Phenotyping for HIV Clinical Trials
Activating PKC-ε Induces HIV Expression
With Improved Tolerability
COVID-19 Research
Safety and Efficacy of Remdesivir in a
Pediatric COVID-19 Population
Treatment and Outcomes of COVID-19 in the
U.S.: Are They Different According to Race?
Acute Kidney Injury in Patients With
Moderate COVID-19 Treated With Remdesivir Versus SoC
Remdesivir Versus Standard of Care for
Severe COVID-19
HCV Research
A Simple and Safe Approach to HCV
Treatment: Findings From the A5360 (MINMON) Trial
For more information, including a complete list of abstracts,
click here.
Please see below for U.S. Indications and Important Safety
Information, including Boxed Warnings, for Biktarvy®, Descovy®,
Descovy for PrEP®, and Epclusa®. Please also see below for U.S.
Indication and Important Safety Information for Veklury®.
Lenacapavir and vesatolimod are investigational compounds and
are not approved by the U.S. Food and Drug Administration or any
other regulatory authority for any use. Their safety and efficacy
are unknown. In May 2019, FDA granted Breakthrough Therapy
Designation for the development of lenacapavir for the treatment of
HIV-1 infection in heavily treatment-experienced patients with
multi-drug resistance.
The use of Biktarvy in individuals with known resistance to the
components of Biktarvy is investigational, and the safety and
efficacy of Biktarvy for this use have not been established.
There is no cure for HIV or AIDS.
U.S. Important Safety Information for
Biktarvy
BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS
B
- Severe acute exacerbations of hepatitis B have been reported
in patients who are coinfected with HIV-1 and HBV and have
discontinued products containing emtricitabine (FTC) and/or
tenofovir disoproxil fumarate (TDF) and may occur with
discontinuation of Biktarvy. Closely monitor hepatic
function with both clinical and laboratory follow-up for at least
several months in patients who are coinfected with HIV-1 and HBV
and discontinue Biktarvy. If appropriate, anti-hepatitis B therapy
may be warranted.
Contraindications
- Coadministration: Do not use Biktarvy with dofetilide or
rifampin.
Warnings and precautions
- Drug interactions: See Contraindications and Drug
Interactions sections. Consider the potential for drug interactions
prior to and during Biktarvy therapy and monitor for adverse
reactions.
- Immune reconstitution syndrome, including the occurrence
of autoimmune disorders with variable time to onset, has been
reported.
- New onset or worsening renal impairment: Cases of acute
renal failure and Fanconi syndrome have been reported with the use
of tenofovir prodrugs. In clinical trials of Biktarvy, there have
been no cases of Fanconi syndrome or proximal renal tubulopathy
(PRT). Do not initiate Biktarvy in patients with estimated
creatinine clearance (CrCl) <30 mL/min. Patients with impaired
renal function and/or taking nephrotoxic agents (including NSAIDs)
are at increased risk of renal-related adverse reactions.
Discontinue Biktarvy in patients who develop clinically significant
decreases in renal function or evidence of Fanconi syndrome. Renal
monitoring: Prior to or when initiating Biktarvy and during
therapy, assess serum creatinine, CrCl, urine glucose, and urine
protein in all patients as clinically appropriate. In patients with
chronic kidney disease, assess serum phosphorus.
- Lactic acidosis and severe hepatomegaly with steatosis:
Fatal cases have been reported with the use of nucleoside analogs,
including FTC and TDF. Discontinue Biktarvy if clinical or
laboratory findings suggestive of lactic acidosis or pronounced
hepatotoxicity develop, including hepatomegaly and steatosis in the
absence of marked transaminase elevations.
Adverse reactions
- Most common adverse reactions (incidence ≥5%; all
grades) in clinical studies through Week 144 were diarrhea (6%),
nausea (6%), and headache (5%).
Drug interactions
- Prescribing information: Consult the full prescribing
information for Biktarvy for more information on Contraindications,
Warnings, and potentially significant drug interactions, including
clinical comments.
- Enzymes/transporters: Drugs that induce P-gp or induce
both CYP3A and UGT1A1 can substantially decrease the concentration
of components of Biktarvy. Drugs that inhibit P-gp, BCRP, or
inhibit both CYP3A and UGT1A1 may significantly increase the
concentrations of components of Biktarvy. Biktarvy can increase the
concentration of drugs that are substrates of OCT2 or MATE1.
- Drugs affecting renal function: Coadministration of
Biktarvy with drugs that reduce renal function or compete for
active tubular secretion may increase concentrations of FTC and
tenofovir and the risk of adverse reactions.
Dosage and administration
- Dosage: Patients weighing ≥25 kg: 1 tablet taken once
daily with or without food.
- Renal impairment: Not recommended in patients with CrCl
<30 mL/min.
- Hepatic impairment: Not recommended in patients with
severe hepatic impairment.
- Prior to or when initiating: Test patients for HBV
infection.
- Prior to or when initiating, and during treatment: As
clinically appropriate, assess serum creatinine, CrCl, urine
glucose, and urine protein in all patients. In patients with
chronic kidney disease, assess serum phosphorus.
Pregnancy and lactation
- Pregnancy: There is insufficient human data on the use
of Biktarvy during pregnancy. Dolutegravir, another integrase
inhibitor, has been associated with neural tube defects. Discuss
the benefit-risk of using Biktarvy during pregnancy and conception.
An Antiretroviral Pregnancy Registry (APR) has been established.
Available data from the APR for FTC shows no difference in the
rates of birth defects compared with a U.S. reference
population.
- Lactation: Women infected with HIV-1 should be
instructed not to breastfeed, due to the potential for HIV-1
transmission.
U.S. Indication for
Biktarvy
Biktarvy is indicated as a complete regimen for the treatment of
HIV-1 infection in adults and pediatric patients weighing at least
25 kg who have no antiretroviral (ARV) treatment history or to
replace the current ARV regimen in those who are virologically
suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen
with no history of treatment failure and no known resistance to any
component of Biktarvy.
U.S. Important Safety Information for
Descovy for PrEP
BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF DESCOVY
FOR PrEP IN UNDIAGNOSED EARLY HIV-1 INFECTION and POST TREATMENT
ACUTE EXACERBATION OF HEPATITIS B
- Descovy for PrEP must be prescribed only to patients confirmed
to be HIV negative immediately prior to initiation and at least
every 3 months during use. Drug-resistant HIV-1 variants have been
identified with use of emtricitabine/tenofovir disoproxil
fumarate
- (FTC/TDF) for HIV-1 PrEP following undetected acute HIV-1
infection. Do not initiate if signs or symptoms of acute HIV-1
infection are present unless HIV-negative status is confirmed.
- Severe acute exacerbations of hepatitis B have been reported in
patients infected with hepatitis B virus (HBV) who discontinued
products containing FTC and/or TDF and may occur with
discontinuation of Descovy. Closely monitor hepatic function with
both clinical and laboratory follow-up for at least several months
in patients with HBV who discontinue Descovy. If appropriate,
anti-hepatitis B therapy may be warranted.
Contraindication:
- Descovy for PrEP is contraindicated in patients with unknown or
positive HIV status.
Comprehensive management to reduce risks:
- Use Descovy for PrEP to reduce the risk of HIV-1 infection as
part of a comprehensive strategy that includes adherence to daily
dosing and safer sex practices, including condoms, to reduce the
risk of sexually transmitted infections (STIs).
- HIV-1 risk factors: Behavioral, biological, or
epidemiologic HIV-1 risk factors may include, but are not limited
to: condomless sex, past or current STIs, self-identified HIV risk,
having sexual partners of unknown HIV-1 viremic status, or sexual
activity in a high-prevalence area or network.
- Reduce STI risk: Counsel on the use of STI prevention
measures (e.g., consistent and correct condom use, knowledge of
partner's HIV-1 viremic status, regular testing for STIs).
- Reduce potential for drug resistance: Only prescribe
Descovy for PrEP to patients confirmed to be HIV negative
immediately prior to initiation, at least every 3 months while
taking Descovy, and upon an STI diagnosis. HIV-1 resistance
substitutions may emerge in patients with undetected HIV-1
infection who are taking only Descovy because Descovy alone is not
a complete regimen for treating HIV-1.
- Some HIV tests may not detect acute HIV infection. Prior to
initiating Descovy for PrEP, ask patients about potential recent
exposure events. If recent (<1 month) exposures are reported or
suspected, or symptoms of acute HIV infection (e.g., fever,
fatigue, myalgia, skin rash) are present, confirm HIV-negative
status with a test approved by the FDA for use in the diagnosis of
acute HIV infection.
- If HIV-1 infection is suspected or if symptoms of acute
infection are present while taking Descovy for PrEP, convert the
Descovy for PrEP regimen to a complete HIV treatment regimen until
HIV-negative status is confirmed by a test approved by the FDA for
use in the diagnosis of acute HIV infection.
- Counsel on adherence: Counsel patients to strictly
adhere to daily dosing, as efficacy is strongly correlated with
adherence. Some patients, such as adolescents, may benefit from
more frequent visits and counseling.
Warnings and precautions:
- New onset or worsening renal impairment: Cases of acute
renal failure and Fanconi syndrome have been reported with the use
of tenofovir prodrugs. Do not initiate Descovy in patients with
estimated creatinine clearance (CrCl) <30 mL/min. Patients with
impaired renal function and/or taking nephrotoxic agents (including
NSAIDs) are at increased risk of renal-related adverse reactions.
Discontinue Descovy in patients who develop clinically significant
decreases in renal function or evidence of Fanconi syndrome.
Monitor renal function in all patients (see Dosage and
Administration section).
- Lactic acidosis and severe hepatomegaly with steatosis:
Fatal cases have been reported with the use of nucleoside analogs,
including FTC and TDF. Discontinue use if clinical or laboratory
findings suggestive of lactic acidosis or pronounced hepatotoxicity
develop, including hepatomegaly and steatosis in the absence of
marked transaminase elevations.
Adverse reactions:
- Most common adverse reactions (≥2%) in the Descovy for PrEP
clinical trial were diarrhea, nausea, headache, fatigue, and
abdominal pain.
Drug interactions:
- Prescribing information: Consult the full Prescribing
Information for Descovy for more information, warnings, and
potentially significant drug interactions, including clinical
comments.
- Metabolism: Drugs that inhibit P-gp can increase the
concentrations of tenofovir alafenamide (TAF), a component of
Descovy. Drugs that induce P-gp can decrease the concentrations of
TAF, which may lead to loss of efficacy.
- Drugs affecting renal function: Coadministration of
Descovy with drugs that reduce renal function or compete for active
tubular secretion may increase concentrations of FTC and tenofovir
and the risk of adverse reactions.
Dosage and administration:
- Dosage: One tablet taken once daily with or without
food.
- HIV screening: Test for HIV-1 infection immediately
prior to initiating, at least every 3 months during use, and upon
diagnosis of an STI (see Warnings and Precautions section).
- HBV screening: Test for HBV infection prior to or when
initiating Descovy.
- Renal impairment and monitoring: Not recommended in
patients with creatinine clearance (CrCl) <30 mL/min. Prior to
or when initiating Descovy, and during use on a clinically
appropriate schedule, assess serum creatinine, CrCl, urine glucose,
and urine protein in all patients. In patients with chronic kidney
disease, assess serum phosphorus.
U.S. Indication for Descovy for
PrEP
Descovy for PrEP is indicated in at-risk adults and adolescents
(≥35 kg) to reduce the risk of sexually acquired HIV-1 infection,
excluding individuals at risk from receptive vaginal sex.
HIV-1–negative status must be confirmed immediately prior to
initiation.
Limitation of Use:
- Descovy for PrEP is not indicated in individuals at risk of
HIV-1 from receptive vaginal sex because effectiveness in this
population has not been evaluated.
U.S. Important Safety Information for
Epclusa
BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN
HCV/HBV COINFECTED PATIENTS
Test all patients for evidence of current or prior hepatitis
B virus (HBV) infection before initiating treatment with Epclusa.
HBV reactivation has been reported in HCV/HBV coinfected patients
who were undergoing or had completed treatment with HCV
direct-acting antivirals (DAAs) and were not receiving HBV
antiviral therapy. Some cases have resulted in fulminant hepatitis,
hepatic failure, and death. Cases have been reported in patients
who are HBsAg positive, in patients with serologic evidence of
resolved HBV, and also in patients receiving certain
immunosuppressant or chemotherapeutic agents; the risk of HBV
reactivation associated with treatment with HCV DAAs may be
increased in patients taking these other agents. Monitor HCV/HBV
coinfected patients for hepatitis flare or HBV reactivation during
HCV treatment and post-treatment follow-up. Initiate appropriate
patient management for HBV infection as clinically
indicated.
Contraindications
- If Epclusa is used in combination with ribavirin (RBV), all
contraindications, warnings and precautions, in particular
pregnancy avoidance, and adverse reactions to RBV also apply. Refer
to RBV prescribing information.
Warnings and Precautions
- Serious Symptomatic Bradycardia When Coadministered with
Amiodarone: Amiodarone is not recommended for use with Epclusa
due to the risk of symptomatic bradycardia, particularly in
patients also taking beta blockers or with underlying cardiac
comorbidities and/or with advanced liver disease. A fatal cardiac
arrest was reported in a patient taking amiodarone who was
coadministered a sofosbuvir-containing regimen. In patients without
alternative viable treatment options, cardiac monitoring is
recommended. Patients should seek immediate medical evaluation if
they develop signs or symptoms of bradycardia.
- Risk of Reduced Therapeutic Effect Due to Concomitant Use of
Epclusa with P-gp Inducers and/or Moderate to Strong Inducers of
CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and
carbamazepine are not recommended for use with Epclusa as they may
significantly decrease sofosbuvir and/or velpatasvir plasma
concentrations.
Adverse Reactions
- The most common adverse reactions (≥10%, all grades) with
Epclusa were headache and fatigue; and when used with RBV in
decompensated cirrhotics were fatigue, anemia, nausea, headache,
insomnia, and diarrhea.
Drug Interactions
- Coadministration of Epclusa is not recommended with topotecan
due to increased concentrations of topotecan.
- Coadministration of Epclusa is not recommended with proton-pump
inhibitors, phenobarbital, phenytoin, rifabutin, rifapentine,
efavirenz, and tipranavir/ritonavir due to decreased concentrations
of sofosbuvir and/or velpatasvir.
Consult the full Prescribing Information for Epclusa for more
information on potentially significant drug interactions, including
clinical comments.
U.S. Indication for
Epclusa
Epclusa is indicated for the treatment of patients 6 years of
age and older or weighing at least 17 kg with chronic hepatitis C
virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without
cirrhosis or with compensated cirrhosis and in combination with
ribavirin for those with decompensated cirrhosis.
U.S. Important Safety Information for
Veklury
Contraindication
- Veklury is contraindicated in patients with a history of
clinically significant hypersensitivity reactions to Veklury or any
of its components.
Warnings and precautions
- Hypersensitivity, including infusion-related and anaphylactic
reactions: Hypersensitivity, including infusion-related and
anaphylactic reactions, has been observed during and following
administration of Veklury. Monitor patients under close medical
supervision for hypersensitivity reactions during and following
administration of Veklury. Symptoms may include hypotension,
hypertension, tachycardia, bradycardia, hypoxia, fever, dyspnea,
wheezing, angioedema, rash, nausea, diaphoresis, and shivering.
Slower infusion rates (maximum infusion time ≤120 minutes) can
potentially prevent these reactions. If a severe infusion-related
hypersensitivity reaction occurs, immediately discontinue Veklury
and initiate appropriate treatment (see Contraindications).
- Increased risk of transaminase elevations: Transaminase
elevations have been observed in healthy volunteers and in patients
with COVID-19 who received Veklury; these elevations have also been
reported as a clinical feature of COVID-19. Perform hepatic
laboratory testing in all patients (see Dosage and administration).
Consider discontinuing Veklury if ALT levels increase to >10x
ULN. Discontinue Veklury if ALT elevation is accompanied by signs
or symptoms of liver inflammation.
- Risk of reduced antiviral activity when coadministered with
chloroquine or hydroxychloroquine: Coadministration of Veklury with
chloroquine phosphate or hydroxychloroquine sulfate is not
recommended based on data from cell culture experiments,
demonstrating potential antagonism, which may lead to a decrease in
antiviral activity of Veklury.
Adverse reactions
- The most common adverse reaction (≥5% all grades) was
nausea.
- The most common lab abnormalities (≥5% all grades) were
increases in ALT and AST.
Drug interactions
- Drug interaction trials of Veklury and other concomitant
medications have not been conducted in humans.
Dosage and administration
- Dosage: For adults and pediatric patients ≥12 years old and
weighing ≥40 kg: 200 mg on Day 1, followed by once-daily
maintenance doses of 100 mg from Day 2 administered only via
intravenous infusion over 30 to 120 minutes.
- Treatment duration: For patients not requiring invasive
mechanical ventilation and/or extracorporeal membrane oxygenation
(ECMO): 5 days; may be extended up to 5 additional days (10 days
total) if clinical improvement is not observed. For patients
requiring invasive mechanical ventilation and/or ECMO: 10
days.
- Testing prior to and during treatment: Perform eGFR, hepatic
laboratory, and prothrombin time testing prior to initiating
Veklury and during use as clinically appropriate.
- Renal impairment: Veklury is not recommended in individuals
with eGFR <30 mL/min.
- Dose preparation and administration: See full Prescribing
Information.
Pregnancy and lactation
- Pregnancy: There are insufficient human data on the use of
Veklury during pregnancy. Pregnant women hospitalized with COVID-19
are at risk for serious morbidity and mortality. Veklury should be
used during pregnancy only if the potential benefit justifies the
potential risk for the mother and the fetus.
- Lactation: It is not known whether Veklury can pass into breast
milk. Breastfeeding individuals with COVID-19 should follow
practices according to clinical guidelines to avoid exposing the
infant to COVID-19.
U.S. Indication for
Veklury
Veklury is indicated for adults and pediatric patients (12 years
of age and older and weighing at least 40 kg) for the treatment of
COVID-19 requiring hospitalization. Veklury should only be
administered in a hospital or in a healthcare setting capable of
providing acute care comparable to inpatient hospital care.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has
pursued and achieved breakthroughs in medicine for more than three
decades, with the goal of creating a healthier world for all
people. The company is committed to advancing innovative medicines
to prevent and treat life-threatening diseases, including HIV,
viral hepatitis and cancer. Gilead operates in more than 35
countries worldwide, with headquarters in Foster City,
California.
For more than 30 years, Gilead has been a leading innovator in
the field of HIV, driving advances in treatment, prevention,
testing and linkage to care, and cure research. Today, millions of
people living with HIV globally receive antiretroviral therapy
provided by Gilead or one of the company’s manufacturing
partners.
Forward-Looking
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors,
including the possibility of unfavorable results from ongoing and
additional clinical trials, including those involving Biktarvy,
Descovy for PrEP, Epclusa, Veklury, lenacapavir and vesatolimod and
the possibility that Gilead may be unable to complete one or more
of such trials in the currently anticipated timelines or at all. In
addition, it is possible that Gilead may make a strategic decision
to discontinue development of lenacapavir and vesatolimod, or that
FDA and other regulatory agencies may not approve lenacapavir or
GS-CA1, and any marketing approvals, if granted, may have
significant limitations on its use. As a result, lenacapavir and
vesatolimod may never be successfully commercialized. These and
other risks are described in detail from time to time in Gilead’s
periodic reports filed with the U.S. Securities and Exchange
Commission, including current reports on Form 8-K, quarterly
reports on Form 10-Q and annual reports on Form 10-K. These risks,
uncertainties and other factors could cause actual results to
differ materially from those referred to in the forward-looking
statements. All statements other than statements of historical fact
are statements that could be deemed forward-looking statements.
Investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and
uncertainties and are cautioned not to place undue reliance on
these forward-looking statements. All forward-looking statements
are based on information currently available to Gilead, and Gilead
assumes no obligation to update any such forward-looking
statements.
U.S. Prescribing Information for Biktarvy,
Descovy for PrEP, and Epclusa including BOXED WARNINGS, and
U.S. Prescribing Information for Veklury, are available at
www.gilead.com.
Biktarvy, Descovy for PrEP, Epclusa, Veklury,
Gilead and the Gilead logo are registered trademarks of Gilead
Sciences, Inc., or its related companies.
For more information about Gilead, please visit
the company’s website at www.gilead.com, follow Gilead on Twitter
(@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5
or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210302006165/en/
Jacquie Ross, Investors (650) 425-8408
Brian Plummer, Media (202) 309-5207
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024